INDIAGLYCO India Glycols Q4 FY26 results (Jan–Mar 2026) and concall
India Glycols reported a strong FY26 with double-digit growth in net revenue, EBITDA, and PAT, driven by robust performance in Potable Spirits and Bio-Fuels. The company also improved its balance sheet metrics, including debt-to-equity and interest coverage. While the Chemicals segment faced full-year revenue decline, Q4 showed a turnaround, and management is optimistic about its future growth, alongside strategic diversification in Ennature Biopharma and continued premiumization in Potable Spirits.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 13.3%, net profit up 120.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 961 | 975 | 863 | 1,040 | 1,091 +14% | 1,102 +13% | 978 +13% |
| EBITDA | 116 | 124 | 144 | 148 | 158 +36% | 176 +42% | 164 +14% |
| Net profit | 39 | 44 | 50 | 53 | 54 +38% | 65 +48% | 110 +120% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
